Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial
暂无分享,去创建一个
Ameet Bakhai | Chunxue Shi | Tara Lavelle | Jeffrey W Moses | Martin B Leon | David J Cohen | J. Moses | M. Leon | T. Lavelle | D. Cohen | R. Kuntz | J. Carrozza | Richard E Kuntz | J. Zidar | A. Bakhai | Joseph P Carrozza | Louise Githiora | Ronna H Berezin | James P Zidar | R. Berezin | C. Shi | Louise Githiora | D. Cohen | D. Cohen
[1] P. Teirstein,et al. Cost-Effectiveness of Gamma Radiation for Treatment of In-Stent Restenosis: Results From the Gamma-1 Trial , 2002, Circulation.
[2] Richard Siegrist,et al. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. , 2003, American heart journal.
[3] J. Spinelli,et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. , 1999, The New England journal of medicine.
[4] Economic impact of drug-eluting stents on hospital systems: a disease-state model. , 2004 .
[5] William W O'Neill,et al. Drug-eluting stents: costs versus clinical benefit. , 2003, Circulation.
[6] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[7] G. Stone,et al. Cost-Effectiveness of Coronary Stenting in Acute Myocardial Infarction: Results From the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial , 2001, Circulation.
[8] Antonio Colombo,et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.
[9] W. Weintraub,et al. Long‐term Clinical Follow‐up in Patients With Angiographic Restudy After Successful Angioplasty , 1993, Circulation.
[10] J. Brophy. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. , 2000, The New England journal of medicine.
[11] D. Mark,et al. Medical economics and the assessment of value in cardiovascular medicine: Part I. , 2002, Circulation.
[12] D. Cohen,et al. Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. , 2004, Health policy.
[13] A. Jacobs,et al. Percutaneous Coronary Intervention in the Current Era Compared With 1985–1986: The National Heart, Lung, and Blood Institute Registries , 2000, Circulation.
[14] W Rutsch,et al. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. , 2001, Journal of the American College of Cardiology.
[15] R. Califf,et al. Economic impact of drug-eluting stents on hospital systems: a disease-state model. , 2004, American heart journal.
[16] H. Krumholz,et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty. Results from a randomized clinical trial. Stent Restenosis Study Investigators. , 1995, Circulation.
[17] Ousa,et al. A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION , 2002 .
[18] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[19] D. Baim,et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. , 2002, Journal of the American College of Cardiology.